摘要
目的观察艾素联合希罗达治疗蒽环类失败复发转移性乳腺癌的临床疗效和毒副反应。方法艾素75mg／m^2，静脉滴注1h，第1天；希罗达2000mg／m^2分2次口服，连续服用2周；用艾素前1天开始口服地塞米松8mg，每天2次，连续3d。每21d为1周期，至少应用2周期后评价疗效。结果全部18例可评价疗效，平均化疗4个周期。完全缓解（CR）4例，部分缓解（PR）6例，稳定（SD）4例，进展（PD）4例，有效率55．6％（10／18）。疾病进展时间（TTP）7．5个月，中位生存时间（MST）12．5个月。最常见的毒副反应为粒细胞减少，其中Ⅲ-Ⅳ度占50．O％，其次为手足综合征，Ⅱ-Ⅲ级占22，2％。结论艾素联合希罗达治疗使用蒽环类失败复发转移性乳腺癌疗效确切，毒副反应可耐受。
Objective To investigate the efficacy and toxicity of docetaxel combined with xeloda in the treatment of patients with anthracycline-resistant metastatic breast cancer. Methods Docetaxel 75 mg/m^2 i. v infusion for 1 hour for the first day, xeloda 2 000 mg/m^2 in divided doses daily for 2 weeks . 1 cycle was 21 days. Evaluations were performed after 2 cycles. Results All patients completed on average four cycles. The overall response rate was 55.6% , including complete response 4 cases, partial response 6 cases, stable disease 4 cases, and progressive disease 4 cases. Median time of disease was 7.5 months, the median survival time was 12.5 months. The major toxicity was leukopenia （50.0% in grade Ⅱ-Ⅲ ） and hand-foot syndrome（22.2% in grade Ⅱ-Ⅲ ）. Conclusions Docetaxel combined with xeloda is active for the patients with anthracycline-resistant metastatic breast cancer with acceptable tolerance.
出处
《肿瘤基础与临床》
2007年第6期508-509,共2页
journal of basic and clinical oncology
关键词
艾素
希罗达
转移性乳腺癌
化疗
docetaxel
xeloda
metastatic breast cancer
chemortherapy
